Investor Relations

Arbutus Biopharma is a publicly-traded (NASDAQ:ABUS) biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection, a disease of the liver caused by hepatitis B virus (HBV). We are developing a portfolio of drug candidates with multiple mechanisms of action that we believe will result in a combination therapy that will transform the HBV treatment landscape and cure hepatitis B virus disease.


In addition to our HBV Assets, we are developing a pipeline of Oncology, Anti-viral and Metabolic Programs that leverage our expertise in RNA interference (RNAi) therapeutics and our Lipid Nanoparticle (LNP) technology.

View all »   RSSRecent Releases

Feb 4, 2016
Arbutus to Participate in Upcoming Investor Conferences

Jan 10, 2016
Arbutus Provides a Corporate Update and Outlines 2016 Milestones

View all »Events & Presentations

Feb 23, 2016
RBC Capital Markets 2016 Global Healthcare Conference

Feb 11, 2016
LEERINK Partners 5th Annual Global Healthcare Conference